Celgene Corporation (CELG): Price Target and June Short Interest Disclosure

Celgene Corporation (CELG) : 14 Wall Street analysts covering Celgene Corporation (CELG) believe that the average level the stock could reach for the short term is $142.36. The maximum price target given is $162 and the minimum target for short term is around $120, hence the standard deviation is calculated at $14.01.

Celgene Corporation (CELG), A drop of 85,666 shares or 1% was seen in the short interest of Celgene Corporation. Even as the interest dropped from 8,397,771 shares on June 15,2016 to 8,312,105 shares on June 30,2016, the days to cover came in at 1. The updated interest stood at 1.1% of the stocks floats. The stock has seen an average daily volume of 5,885,845 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Equity analysts at the Brokerage firm BTIG Research downgrades its rating on Celgene Corporation (NASDAQ:CELG). The rating major has initiated the coverage with neutral rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on June 1, 2016.


Celgene Corporation (NASDAQ:CELG): On Thursdays trading session , Opening price of the stock was $102.95 with an intraday high of $103.14. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $100.8589. However, the stock managed to close at $101.42, a loss of 0.33% for the day. On the previous day, the stock had closed at $101.76. The total traded volume of the day was 5,392,013 shares.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.